-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 2, 2021, Renew Bioscience announced that a medical device named Cerezen has been granted breakthrough medical device designation by the US FDA for the treatment of mild cognitive impairment (MCI) caused by Alzheimer’s disease, and Alzheimer's type mild dementia
An important risk factor for Alzheimer's disease-related cognitive impairment and dementia is the patient's poor vascular health.
Cerezen uses external counterpulsation (External Counterpulsation, ECP) therapy, which can enhance the patient's blood flow and overall cardiovascular system efficiency
▲Cerezen's steps and mechanism of action (picture source: Renew Bioscience's official website)
Reference materials:
[1] FDA grants Breakthrough status for Alzheimer's treatment.